STOCK TITAN

Venus Concept Announces Australian Regulatory Approval for Venus Bliss MAX

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Venus Concept Inc. (NASDAQ: VERO) has received clearance from the Therapeutic Goods Administration (TGA) in Australia to market its Venus Bliss MAX system. This flagship platform offers a comprehensive body treatment solution, combining three of Venus Concept's leading technologies:

1. Proprietary (MP)2 applicator for cellulite reduction and skin treatments
2. FlexMax EMS applicators for muscle conditioning
3. Diode laser for fat reduction treatments

The Venus Bliss MAX is already available in select markets globally and has received positive feedback from service providers. Dr. Hemanth Varghese, President and COO of Venus Concept, expressed confidence that the system's success will be replicated in Australia.

Venus Concept Inc. (NASDAQ: VERO) ha ricevuto l'autorizzazione dall'Amministrazione per i beni terapeutici (TGA) in Australia per commercializzare il suo Venus Bliss MAX system. Questa piattaforma di punta offre una soluzione completa per il trattamento del corpo, combinando tre delle tecnologie leader di Venus Concept:

1. Applicatore proprietario (MP)2 per la riduzione della cellulite e trattamenti della pelle
2. Applicatori FlexMax EMS per il condizionamento muscolare
3. Laser a diodo per trattamenti di riduzione del grasso

Il Venus Bliss MAX è già disponibile in mercati selezionati a livello globale e ha ricevuto feedback positivi dai fornitori di servizi. Dr. Hemanth Varghese, Presidente e COO di Venus Concept, ha espresso fiducia che il successo del sistema sarà replicato in Australia.

Venus Concept Inc. (NASDAQ: VERO) ha recibido la aprobación de la Administración de Bienes Terapéuticos (TGA) en Australia para comercializar su Venus Bliss MAX system. Esta plataforma insignia ofrece una solución integral para el tratamiento corporal, combinando tres de las tecnologías líderes de Venus Concept:

1. Aplicador propietario (MP)2 para la reducción de la celulitis y tratamientos de la piel
2. Aplicadores FlexMax EMS para el acondicionamiento muscular
3. Láser de diodo para tratamientos de reducción de grasa

El Venus Bliss MAX ya está disponible en mercados seleccionados a nivel mundial y ha recibido comentarios positivos de los proveedores de servicios. El Dr. Hemanth Varghese, Presidente y COO de Venus Concept, expresó su confianza en que el éxito del sistema se replicará en Australia.

Venus Concept Inc. (NASDAQ: VERO)는 호주에서 Therapeutic Goods Administration (TGA)로부터 Venus Bliss MAX system의 판매 승인을 받았습니다. 이 주력 플랫폼은 Venus Concept의 세 가지 주요 기술을 결합하여 포괄적인 신체 치료 솔루션을 제공합니다:

1. 셀룰라이트 감소 및 피부 치료를 위한 독점 (MP)2 어플리케이터
2. 근육 조화를 위한 FlexMax EMS 어플리케이터
3. 지방 감소 치료를 위한 다이오드 레이저

Venus Bliss MAX는 이미 전 세계의 특정 시장에서 사용할 수 있으며, 서비스 제공자로부터 긍정적인 피드백을 받았습니다. Venus Concept의 사장 겸 COO인 Dr. Hemanth Varghese는 이 시스템의 성공이 호주에서도 재현될 것이라고 확신했습니다.

Venus Concept Inc. (NASDAQ: VERO) a reçu l'autorisation de la Therapeutic Goods Administration (TGA) en Australie de commercialiser son Venus Bliss MAX system. Cette plateforme phare propose une solution complète pour le traitement corporel, combinant trois des principales technologies de Venus Concept :

1. Applicateur propriétaire (MP)2 pour la réduction de la cellulite et les traitements cutanés
2. Applicateurs FlexMax EMS pour le conditionnement musculaire
3. Laser à diode pour les traitements de réduction des graisses

Le Venus Bliss MAX est déjà disponible sur certains marchés mondiaux et a reçu des retours positifs de la part des prestataires de services. Dr. Hemanth Varghese, Président et COO de Venus Concept, a exprimé sa confiance dans le fait que le succès du système sera reproduit en Australie.

Venus Concept Inc. (NASDAQ: VERO) hat die Genehmigung von der Therapeutic Goods Administration (TGA) in Australien erhalten, um ihr Venus Bliss MAX system zu vermarkten. Diese Flaggschiff-Plattform bietet eine umfassende Lösung zur Körperbehandlung und kombiniert drei der führenden Technologien von Venus Concept:

1. Proprietärer (MP)2-Applikator zur Cellulite-Reduzierung und Hautbehandlungen
2. FlexMax EMS-Applikatoren zur Muskelkonditionierung
3. Diodenlaser zur Fettreduzierung

Das Venus Bliss MAX ist bereits in ausgewählten Märkten weltweit verfügbar und hat positive Rückmeldungen von Dienstleistern erhalten. Dr. Hemanth Varghese, Präsident und COO von Venus Concept, äußerte das Vertrauen, dass der Erfolg des Systems auch in Australien wiederholt werden wird.

Positive
  • Received regulatory approval for Venus Bliss MAX in Australia
  • Expansion into new market with flagship product
  • Positive feedback from existing markets
Negative
  • None.

The TGA approval for Venus Bliss MAX in Australia marks a significant milestone for Venus Concept. This multi-functional platform combines three advanced technologies for comprehensive body treatments, potentially positioning the company as a strong competitor in the Australian aesthetic market.

The device's versatility, offering cellulite reduction, skin treatments, muscle conditioning and fat reduction in one system, could be appealing to clinics looking to expand their services without investing in multiple machines. This cost-effective approach might drive adoption among Australian aesthetic providers.

However, success will depend on factors like pricing strategy, training support and marketing efforts. The Australian market's response and the system's performance compared to existing solutions will be important in determining its impact on Venus Concept's market share and revenue growth in the region.

The Australian aesthetic device market presents a significant opportunity for Venus Concept. With a growing demand for non-invasive body contouring treatments, the Venus Bliss MAX's all-in-one approach could resonate well with both clinicians and consumers.

Key factors to watch include:

  • Market penetration rate compared to established competitors
  • Pricing strategy and its alignment with the Australian market
  • Clinical outcomes and customer satisfaction in real-world settings

The success of Venus Bliss MAX in Australia could serve as a springboard for expansion into other Asia-Pacific markets. However, the company must navigate regulatory landscapes and tailor its marketing approach to local preferences to maximize its potential in the region.

While the TGA approval is positive news for Venus Concept, investors should temper their expectations. The company's Q2 2023 revenue was $18.9 million, down 19% year-over-year, indicating ongoing challenges. The Australian market alone is unlikely to dramatically alter the company's financial trajectory in the short term.

Key financial considerations include:

  • Potential impact on revenue growth in upcoming quarters
  • Margins on the Venus Bliss MAX system compared to other products
  • Marketing and distribution costs associated with the Australian launch

Investors should monitor the adoption rate and revenue contribution from the Australian market in future earnings reports to gauge the true impact of this regulatory approval on Venus Concept's financial health.

TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has clearance from the Therapeutic Goods Administration (TGA) in Australia to market the Venus Bliss MAX system. The Venus Bliss MAX is the Company’s flagship platform that offers a comprehensive, world-class solution for all customers’ body treatment needs and is currently available in select markets globally.

Featuring three of Venus Concept’s market leading technologies in one, the Venus Bliss MAX is a body shaping solution consisting of our proprietary (MP)2 applicator that combines Multi-Polar Radio Frequency with Pulsed Electro Magnetic Fields and advanced VariPulse™ technology for Cellulite Reduction and Skin treatments, Venus’ FlexMax EMS applicators for Muscle Conditioning and a diode laser for Fat Reduction treatments.

“We are excited to introduce to the Australian market the Venus Bliss MAX, our device that offers aesthetic clinicians an all-in-one body solution to customers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept. “The Venus Bliss Max continues to receive strong positive feedback globally from service providers of its complete body offering, and we are confident the same success will be replicated in Australia.”

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, and projections about our business, and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A-“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A-“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.


FAQ

What regulatory approval did Venus Concept (VERO) receive in Australia?

Venus Concept (VERO) received clearance from the Therapeutic Goods Administration (TGA) in Australia to market its Venus Bliss MAX system.

What technologies does the Venus Bliss MAX system offer?

The Venus Bliss MAX system combines three technologies: (MP)2 applicator for cellulite reduction and skin treatments, FlexMax EMS applicators for muscle conditioning, and a diode laser for fat reduction treatments.

When did Venus Concept (VERO) announce the Australian regulatory approval?

Venus Concept (VERO) announced the Australian regulatory approval for Venus Bliss MAX on September 18, 2024.

Is the Venus Bliss MAX system available in other markets besides Australia?

Yes, the Venus Bliss MAX system is currently available in select markets globally, with Australia being a new addition.

Venus Concept Inc.

NASDAQ:VERO

VERO Rankings

VERO Latest News

VERO Stock Data

4.65M
7.26M
6.08%
42.76%
1.26%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
TORONTO